Pipeline
Umoja’s VivoVec-driven pipeline is driving numerous near-term catalysts
Program
Preclinical
PHASE 1
UB-VV400/410
NHL/Autoimmune
Preclinical
PHASE 1
Target
CD22
Milestone
Clinic 2025
In-Licensing Partner
IASO Biotherapeutics
NCT06743503
UB-VV300/310
NHL/Autoimmune
Preclinical
PHASE 1
Target
CD20
Milestone
IND enabling
UB-VV500
Multiple Myeloma
Preclinical
PHASE 1
Target
Undisclosed
Milestone
IND enabling
UB-VV111
Hematology
Preclinical
PHASE 1
Target
CD19
Milestone
Clinic 2025
Out-Licensing Partner
AbbVie
NCT06528301
Multiple
Hematology
Preclinical
PHASE 1
Target
Undisclosed
Milestone
Early development
Out-Licensing Partner
AbbVie
Multiple
Oncology
Preclinical
PHASE 1
Target
Undisclosed
Milestone
Early development
Out-Licensing Partner
AbbVie
